876147-67-0

Usage

Molecular structure

The compound consists of a piperidine ring, a thiazolyl group, and a chlorophenyl group.

Ester functional group

It is an ester formed from 1-piperidinecarboxylic acid and thiazolyl acetyl amino.

Pharmaceutical applications

It has potential applications in the pharmaceutical industry as a building block in the synthesis of various pharmaceutical drugs.

Versatile structure

The compound's structure allows for modifications and adaptations in drug synthesis.

Pharmacological properties

The presence of the piperidine ring, thiazolyl group, and chlorophenyl group may contribute to its potential pharmacological properties.

Value in research and development

The compound is a valuable asset for pharmaceutical research and development due to its potential therapeutic applications and versatile structure.

Upstream product

• 17969-41-4 [2-(4-chloro-phenyl)-4-methyl-thiazol-5-yl]-acetic acid 
• 144243-24-3 tert‐butyl 3‐aminopiperidine‐1‐carboxylate 

Downstream Products

• 876147-68-1 N-(piperidin-3-yl)-2-[2-(4-chlorophenyl)-4-methylthiazol-5-yl] acetamide 

Relevant academic research and scientific papers

Discovery of cyclic amine-substituted benzoic acids as PPARα agonists

A series of novel cyclic amine-substituted benzoic acid derivatives were synthesized and evaluated for their PPARα agonist activity. Strucure-activity relationship studies led to the identification of (S)-3-[3-[2-(4-chlorophenyl)-4-methylthyazole-5-carboxamido]piperidin-1-yl] benzoic acid (S)-4f (KRP-105) as a potent and high subtype-selective human PPARα agonist. (S)-4f showed excellent PK profile and oral administration of (S)-4f to high-fat diet dogs effectively lowered triglycerides.

NOVEL CYCLIC AMINOBENZOIC ACID DERIVATIVE

The present invention relates to cyclic amino benzoic acid derivatives which are effective in therapy of lipid metabolism abnormality, diabetes and the like as a human peroxisome proliferators-activated receptor (PPAR) agonist, in particular, as an agonist against human PPARα isoform, and addition salts thereof, and pharmaceutical compositions containing these compounds. A cyclic amino benzoic acid derivative represented by the general formula (1) [wherein a ring Ar represents an aryl group which may have substituent, or the like; Y represents a C1-C4 alkylene, C2-C4 alkenylene, C2-C4 alkynylene, or the like; Z represents an oxygen atom, sulfur atom or - (CH2)n- (n represents 0,1 or 2) ; X represents a hydrogen atom, halogen atom, lower alkyl group which may be substituted with a halogen atom, or the like; R represents a hydrogen atom or lower alkyl group, and -COOR substitutes for an ortho position or metha position of binding position of ring W] or a pharmaceutically acceptable salt thereof.